Stelara Binding Assays

BioOutsource has extensive experience in the development, optimization and validation of a wide range of different types of binding assays and immunoassays and offers GCP, GLP and GMP-compliant testing services in compliance with EMA and FDA guidelines to support the biopharmaceutical industry.
Using this experience, we have created a range of off-the-shelf binding assays, including Stelara IL-12, IL-12p70, 12-p40, IL-12p80 and IL-23 binding assays, and a Stelara C1q binding assay to support process development, characterization and biosimilarity studies.

Binding assays are employed to study a number of different features of Stelara (ustekinumab) and play a vital role in the development process, by measuring the binding of Stelara to IL-12/IL-23 as well as C1q.  Our range of off-the-shelf binding methods can be used to support the development and characterization of Stelara (ustekinumab), and in the performance of extensive comparability studies:

Our binding assays can be developed using different platforms including ELISA, Electrochemiluminescence (MSD) or Surface Plasmon Resonance (SPR) and can be performed with a variety of different reporting mechanisms to provide you with the comprehensive, industry-leading comparability reports required to understand all aspects of the performance of your Stelara molecule.

BioOutsource offers cost-effective solutions to develop custom methods that are not currently in our portfolio: please contact us to find out more.